MX350206B - Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle). - Google Patents

Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle).

Info

Publication number
MX350206B
MX350206B MX2012006197A MX2012006197A MX350206B MX 350206 B MX350206 B MX 350206B MX 2012006197 A MX2012006197 A MX 2012006197A MX 2012006197 A MX2012006197 A MX 2012006197A MX 350206 B MX350206 B MX 350206B
Authority
MX
Mexico
Prior art keywords
treatment
sle
antibodies
lupus erythematosus
systemic lupus
Prior art date
Application number
MX2012006197A
Other languages
English (en)
Other versions
MX2012006197A (es
Inventor
Bruecher Christoph
Daelken Benjamin
Osterroth Frank
Uherek Christoph
Wartenberg Demand Andrea
Zuber Chantal
Czeloth Niklas
Engling Andre
Roettgen Peter
Gutscher Marcus
Wessels Kranz Judith
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0920940A external-priority patent/GB0920940D0/en
Priority claimed from GB0920942A external-priority patent/GB0920942D0/en
Priority claimed from GB0920933A external-priority patent/GB0920933D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of MX2012006197A publication Critical patent/MX2012006197A/es
Publication of MX350206B publication Critical patent/MX350206B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo humanizado o su fragmento capaz de ligar a interleucina-10 (IL-10), caracterizado porque el anticuerpo o su fragmento comprende una cadena ligera variable que comprende las secuencias de aminoácidos de SEQ ID NO: 71, 72, y 73, y una cadena pesada variable que comprende las secuencias de aminoácidos de SEQ ID NO: 74, 75 Y 76.
MX2012006197A 2009-11-30 2010-11-30 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle). MX350206B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0920940A GB0920940D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920942A GB0920942D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920933A GB0920933D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
PCT/EP2010/068562 WO2011064398A1 (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Publications (2)

Publication Number Publication Date
MX2012006197A MX2012006197A (es) 2012-06-19
MX350206B true MX350206B (es) 2017-08-28

Family

ID=43798505

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012006198A MX343228B (es) 2009-11-30 2010-11-30 Anticuerpos anti-il-10humanizados para el tratamiento de lupus sistémico eritematoso.
MX2012006197A MX350206B (es) 2009-11-30 2010-11-30 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012006198A MX343228B (es) 2009-11-30 2010-11-30 Anticuerpos anti-il-10humanizados para el tratamiento de lupus sistémico eritematoso.

Country Status (17)

Country Link
US (4) US8852871B2 (es)
EP (2) EP2470209B1 (es)
JP (2) JP2013511994A (es)
KR (2) KR101802260B1 (es)
CN (2) CN102711829B (es)
AU (2) AU2010323036B2 (es)
BR (2) BR112012012917A2 (es)
CA (2) CA2782004A1 (es)
CO (1) CO6561779A2 (es)
CR (2) CR20120359A (es)
IL (2) IL219954A (es)
MX (2) MX343228B (es)
NZ (2) NZ600894A (es)
RU (2) RU2581812C2 (es)
SG (2) SG10201407935YA (es)
WO (2) WO2011064398A1 (es)
ZA (1) ZA201204843B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343228B (es) 2009-11-30 2016-10-26 Biotest Ag Anticuerpos anti-il-10humanizados para el tratamiento de lupus sistémico eritematoso.
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
CA2938152A1 (en) * 2014-02-10 2015-08-13 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
US10725030B2 (en) 2014-11-28 2020-07-28 Ge Healthcare Bio-Sciences Ab Method for determining analyte-ligand binding on a sensor surface
KR20170089013A (ko) * 2014-12-15 2017-08-02 모르포시스 아게 Il-17c에 대한 항체
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
WO2019072566A1 (en) 2017-10-10 2019-04-18 Biotest Ag COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER
AR114112A1 (es) 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
JP2023549872A (ja) 2020-11-18 2023-11-29 アストラゼネカ・アクチエボラーグ ステロイド節約
CA3213824A1 (en) * 2021-03-23 2022-09-29 Organogenesis, Inc. Methods, kits, and compositions for characterizing an anti-inflammatory response of a product

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
MX9200161A (es) * 1991-01-16 1992-07-01 Schering Corp Uso de interleucina-10 en inmunoterapia adoptiva de cancer
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE187336T1 (de) 1991-08-06 1999-12-15 Schering Corp Verwendung von interleukin-10 analogen oder antagonisten zur behandlung von endotoxin- oder superantigen induzierter toxizität
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
DE19529026C2 (de) 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
BRPI0316779B1 (pt) 2002-12-16 2020-04-28 Genentech Inc anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
PE20090046A1 (es) * 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
NO2195023T3 (es) 2007-08-29 2018-08-04
MX343228B (es) * 2009-11-30 2016-10-26 Biotest Ag Anticuerpos anti-il-10humanizados para el tratamiento de lupus sistémico eritematoso.

Also Published As

Publication number Publication date
US20120321618A1 (en) 2012-12-20
RU2012127380A (ru) 2014-01-10
JP2013511995A (ja) 2013-04-11
JP6005519B2 (ja) 2016-10-12
MX343228B (es) 2016-10-26
RU2587622C2 (ru) 2016-06-20
KR101802260B1 (ko) 2017-11-28
RU2581812C2 (ru) 2016-04-20
EP2470209A1 (en) 2012-07-04
AU2010323036B2 (en) 2015-01-29
AU2010323037A1 (en) 2012-07-19
MX2012006198A (es) 2012-06-19
BR112012012912A2 (pt) 2016-10-25
CA2782007A1 (en) 2011-06-03
CN102811736A (zh) 2012-12-05
CN102811736B (zh) 2016-01-20
BR112012012917A2 (pt) 2016-10-25
NZ600894A (en) 2014-09-26
NZ600899A (en) 2014-09-26
CN102711829A (zh) 2012-10-03
IL219954A (en) 2016-10-31
JP2013511994A (ja) 2013-04-11
AU2010323037B2 (en) 2015-01-29
CN102711829B (zh) 2016-03-16
SG10201407935YA (en) 2015-01-29
CR20120359A (es) 2013-01-25
ZA201204843B (en) 2020-02-26
KR20120103664A (ko) 2012-09-19
KR101802261B1 (ko) 2017-11-28
US20120321617A1 (en) 2012-12-20
US8852871B2 (en) 2014-10-07
WO2011064399A1 (en) 2011-06-03
AU2010323036A1 (en) 2012-07-19
MX2012006197A (es) 2012-06-19
US20150064179A1 (en) 2015-03-05
EP2470208A1 (en) 2012-07-04
US8956607B2 (en) 2015-02-17
CR20120358A (es) 2013-01-23
CO6561779A2 (es) 2012-11-15
US20150218270A1 (en) 2015-08-06
US9605066B2 (en) 2017-03-28
CA2782007C (en) 2018-07-24
IL219954A0 (en) 2012-07-31
RU2012127381A (ru) 2014-01-10
IL219955A0 (en) 2012-07-31
CA2782004A1 (en) 2011-06-03
US9540436B2 (en) 2017-01-10
KR20120115289A (ko) 2012-10-17
EP2470209B1 (en) 2020-01-01
IL219955A (en) 2016-08-31
WO2011064398A1 (en) 2011-06-03
SG10201407936XA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
MX350206B (es) Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle).
HRP20181245T1 (hr) Anti-cd38 protutijela
MX347020B (es) Anticuerpo contra el csf-1r.
WO2015091914A3 (en) Caninized murine anti-canine pd-1 antibodies
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
MX354243B (es) Polipeptidos anticuerpos que antagonizan cd40.
MX2015015482A (es) Proceso continuo de multiples etapas para purificar anticuerpos.
NZ724296A (en) Antibodies for treatment of cancer expressing claudin 6
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
PT2768857T (pt) Métodos para purificar anticorpos
MX2013013832A (es) Proteínas de unión receptoras fc.
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
SG11201507686TA (en) Pan-ELR<sp>+</sp> CXC CHEMOKINE ANTIBODIES
DK2623592T3 (da) Anti-humane ccr7-antistoffer, hybridom, medicinsk sammensætning og antistof-immobiliseret bærer
MX2013002960A (es) Composiciones de anticuerpo y metodos de uso.
EP2663330A4 (en) ANTIBODIES TO TLR4 AND METHOD FOR THEIR USE
SG10201901695RA (en) Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
WO2012097238A3 (en) Il-27 antagonists for treating inflammatory diseases
ZA201302639B (en) Antibodies for the treatment of hiv
SG11202112846RA (en) Methods for purifying antibodies
WO2013082342A3 (en) Apparatus and method for carbon activation using multi-chamber periodic furnace
Qi-Guang et al. The Relationship between Family and School Reform: the Experience of the West and China's Problem
PL393508A1 (pl) Rekombinowane przeciwciało monoklonalne o wysokim powinowactwie do antygenu bakteryjnego o natywnej i funkcjonalnej strukturze, sposób otrzymywania przeciwciał monoklonalnych oraz zastosowanie rekombinowanych przeciwciał monoklonalnych
UA48244U (ru) Способ индукции механизмов саморегуляции агроценоза ягодников

Legal Events

Date Code Title Description
FG Grant or registration